I caught COVID (and it's still horrible)

I Caught COVID (and it’s still horrible)

At the beginning of this month, my partner and I attended a super-spreader event — GenCon. We masked the entire time, unless we were eating. But, those one-way protections were still not enough to save us.

On the evening of Saturday the 3rd, while still there, my partner tested positive for COVID after only having minor runny nose symptoms and a tickle in their throat.

We drove home overnight. On Sunday, we got them to urgent care for a script of Paxlovid.

Knowing that my positive test would come within days, I spent some of my energy Monday to wrangle a Paxlovid script for myself, which I started on the 6th. It was a good thing, too, as my symptoms really hit hard on the morning of the 6th.

I woke up with a gunky throat, small cough, and some intense chills.

My Paxlovid tips: Take Paxlovid with some food already in your stomach. Follow it up with a lot of water and some more food. These things will help limit the horrid taste that will otherwise float up your throat and into your mouth… and make you want to vomit.

The bulk of my infection was relatively normal. I napped here and there. I had some nasty heartburn.

After sleeping 18/24 hours Saturday and finishing my Paxlovid Sunday, I was finally feeling better — not 100%, but probably 75-80% physically and 90% mentally.

I was very grateful my illness hit a couple days following my partner’s, and that their mom watched the dogs for a few extra days.

By Monday the 12th, I was asymptomatic and testing negative. I still rested a lot over the week, as to not tempt the long COVID deities.

On Thursday evening, I was supposed to fly out to Atlanta to attend the National LGBTQ Health Conference. I woke up that morning with a runny nose, which I had attributed to missing a dose of allergy medication the night before.

But, after hearing about someone else dealing with possible COVID symptoms, I took a home test… which was heavily positive. That line was THICK. A second home test showed positive, too. After a few minutes of crying, I headed over to urgent care for a confirmation PCR test. 

And, of course, I’m in the 20% of people who get rebound COVID.

I canceled my travel plans.

Folks at urgent care were really delightful, and I had wonderful interactions with everyone there. We decided against another round of Paxlovid, mostly because there isn’t much evidence to prove that it’s helpful. The real trick is to just treat and monitor symptoms.

I spent a little over an hour canceling my travel plans and preparing for another several days of isolation.

By the evening, my left eye was leaking sinus fluid along with my left nostril. My left eye was also beginning to swell.

Halfway through the day on Friday, I began to itch all over. By the evening, I figured this was a COVID-related rash, as that’s not uncommon in rebound infections especially. It was bad enough that I had to take dye-free Benadryl to help. My partner drew me a nice, warm bath to relax in for a while, too.

When I woke up at 3:45 am, my Benadryl had worn off… and my whole body was swollen and covered in rash. And that was after two regular antihistamines, adding in another allergy med, dye-free Benadryl, and using my Benadryl anti-itch spray.

My left eye was horribly worse, too.

Grayson with a swollen left eye

After lying awake on my couch for half an hour waiting for another Benadryl to kick in, I began to really grapple with the idea that this rebound COVID infection had sent me into a full-on Still’s Disease flare-up.

Knowing that COVID can cause cytokine storms — and that’s essentially what Macrophage Activation Syndrome is — I had to get medical attention.

I wasn’t bad enough to feel like an ER trip was warranted. So, I set up an urgent care appointment Saturday at 10:30 am. And, I’m glad I did. My rash and swelling continued to progress through the early morning hours. My skin felt bruised because of the inflammation, and my left eye was so swollen that I could not easily find my occipital bone.

For the first time, someone at urgent care KNEW Still’s, and agreed that I needed a prednisone burst. He even asked what dosage I usually start at.

As a rare disease patient, I’m so used to being dismissed or having to completely explain my condition(s) to providers. The fact that I didn’t have to do that felt revolutionary. My Quality of Life went from 4 to 8 over the course of a few hours.

And, honestly? I wanted to cry.

Within just an hour of starting prednisone, my eye got less puffy and I was generally less swollen. My fingers, hands, and wrists were still swollen, but much less so. And, most importantly, I was no longer covered in rash (although I still had a few spots).

When I woke up Sunday, after a full night’s sleep, I was covered in rash again. Thankfully, it was nowhere near as bad as the day before. It easily dissipated after I waited for steroids to kick in. Unfortunately, I developed more congestion symptoms again, including some throat gunk.

With it now being Monday, I’ve begun to cough up more phlegm. This is, in part, because I’ve started to take Mucinex. This mucus is far too thick to cough up without help, at least for me. My Still’s rash is still present, although it continues to fade more a few hours after taking my prednisone burst.

I’ll continue to update here with my experience over the next few days and weeks as necessary.

 

Early September Update

I continued to test positive for COVID until August 25. The last few days were very heavily taxing on my mental health.

My dysautonomia symptoms have drastically returned, too. Not that they were really gone, but they were relatively rare. Now, we’re back to nearly daily incidences of symptoms.

My Still’s Disease is also more active. I’ve had more occurrences of rash, especially following showers.

 

What’s worked well

Your mileage may vary, but this is what has been helpful for me:

  • Having a caring partner, ready and willing to help with literally anything and everything
  • Seeking medical help quickly when needed and being prepared to advocate for myself as needed
  • Mucinex
  • Dye-free Benadryl and anti-itch Benadryl spray
  • Extra anti-histamines (for me, this has meant adding loratadine and the above mentioned Benadryl to my already-daily cetirizine and famotidine)
  • Sitting on a plush blanket to not further anger rash-covered body parts
  • Making sure I eat a little bit every couple of hours, regardless of how hungry I may be
  • Resting in a warm bath
  • Our dogs, who have spent time kissing where my rash has been and cuddling me to help me feel better

Dean sitting on the couch Hank snuggled up by my side

Regardless of whether or not you’ve had COVID yet, please mask. Continue to take other precautions as well, including not meeting in groups even outdoors without masks, washing hands and sanitizing them often, switching out KN95 masks for new ones regularly (at least daily if possible), and possibly using CPC mouthwash and nasal sprays.

Infection numbers are horrible right now and have been for a few weeks.

A map of the United States color-coded in shades of maroon, orange and gray displaying SARS-CoV-2 Wastewater Viral Activity level as of August 1, 2024, where deeper tones correlate to higher viral activity and gray indicates “Insufficient,” or “No Data.” Text above the map reads “Very High” or “High” levels in 44 states. Viral activity is “Moderate” in 4 states, “Low” in 2 states, and data is unavailable for North Dakota, Guam, Puerto Rico, and the U.S. Virgin Islands. At the bottom, text reads People’s CDC. Source: CDC.

People aren’t even testing, thinking they only have allergies or colds. Even for the most healthy person, this is dangerous — but incredibly more so for those of us with underlying health issues.

Still’s Disease Onset After mRNA COVID-19 Vaccine

An 82-year-old woman was diagnosed with still’s disease following an mRNA COVID-19 vaccination. Onset after age 80 is really uncommon, making this an interesting study.

Now, it’s important to remember that these kinds of reactions are incredibly rare. Less than 30 patients have had this happen. Please still get your COVID-19 vaccines if you’re medically able to do so.

Check out the full case study:

Nishioka H, Shirota S (January 02, 2024) Adult-Onset Still’s Disease After an mRNA COVID-19 Vaccine in an Older Woman. Cureus 16(1): e51540. doi:10.7759/cureus.51540

COVID Might Raise Odds for Still’s Disease

That’s according to a new study published this month.

People are at less risk for Still’s than they are for some diseases, suggesting a hierarchy as published in this study.

hierarchy of prevalence

This could also be due to the possibility of Still’s Disease already being a predetermined factor in the body, with COVID merely activating it.

More study is needed.

Lim, Sung Ha & Ju, Hyun & Han, Ju & Lee, Ji & Lee, Won-Soo & Bae, Jung Min & Lee, Solam. (2023). Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19. JAMA Network Open. 6. e2336120. 10.1001/jamanetworkopen.2023.36120.

Taiwan: Actemra Approved to Treat COVID-19

The following is a press release issued today by Chugai Pharmaceutical:

Chugai Pharmaceutical Co., Ltd.(TOKYO: 4519) announced that Chugai Pharma Taiwan Ltd., a wholly-owned subsidiary of Chugai, obtained an import drug license from the Taiwan Food and Drug Administration (TFDA) for Chugai’s Actemra® (tocilizumab) intravenous (IV) formulation for the treatment of COVID-19 in hospitalized adult patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

This approval is based on the results from clinical studies evaluating Actemra in hospitalized patients, including an investigator-initiated, randomized, open-label, platform overseas study (RECOVERY study) and three placebo-controlled, randomized, double-blind, multicenter, global phase III studies conducted by Roche (COVACTA study, EMPACTA study, REMDACTA study).

About Actemra

Actemra is the first therapeutic antibody created in Japan by Chugai. It is designed to block the activity of IL-6, a type of inflammatory cytokine. First launched in June 2005, the intravenous injection is approved for seven indications in Japan: Castleman’s disease, rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, cytokine release syndrome induced by tumor-specific T cell infusion therapy, adult Still’s disease, and SARS-CoV-2 pneumonia. In addition, Actemra subcutaneous injection is approved for three indications in Japan: rheumatoid arthritis, Takayasu arteritis, and giant cell arteritis. Actemra has obtained regulatory approval in more than 110 countries worldwide.

As you may know, Actemra is one of a small number of medications FDA-approved for both SJIA and AOSD.

A New Perspective on COVID-19 Risk Aware Conversations in Healthcare

Following my Cleveland Clinic journey, I sent a follow-up to the provider who ordered testing to talk more. She was not seeing the heart rate change that she expected with POTS. She was concerned, though, about the rise in my systolic BP during the test – especially since my seated BP is always fine.

So, I’ve scheduled a cardiology appointment more locally. Today, while filling out the pre-screening questionnaire, I was delighted to see the way this COVID-19 risk aware conversation was framed.

Importance of a Mask
For an upcoming appointment with
• It is very important that you wear a mask, especially since you are now in a healthcare environment.
• Many of our patients here are at a higher risk for serious injury or death from infection than most people.
• We do everything we can to keep everyone safe: you, our other patients, and everyone taking care of you.
• What we DO know about COVID-19 is that wearing a mask helps you stay safe and helps prevent the spread of the disease to others, especially knowing that we have a number of people here who are at higher risk.
• I am asking you to do something that I am also doing: wearing a mask.
• By wearing a mask, I'm reducing the risk for you, too.
• I ask that you do the same to keep me safer... and the other patients that we treat here.
Thank you for your cooperation.
*Indicates a required field.
*Are you willing to wear a mask?
Yes, willing to wear a hospital provided mask
No, not able or willing

Why in the world is this the first time I’ve seen a good example of this conversation??

What about you – have you seen similar notices?

Extending Telehealth for Medicare Recipients

The following is an email from the US Pain Foundation dated yesterday, March 21:

Since access and coverage of telehealth has been a wonderful and safe convenience for people with chronic pain during the pandemic, we have been closely following government policy around telehealth coverage and want to update you on recent developments.

Last week, President Biden signed into law HR 2471, the Consolidated Appropriations Act of 2022 which finalized the fiscal year 2022 federal budget and included a number of provisions to extend Medicare telehealth coverage implemented as part of the government’s response to COVID-19. The COVID-19 Public Health Emergency (PHE) has not yet officially ended but is expected to end sometime in the next few months. HR 2471 will extend Medicare telehealth coverage for 151 days or approximately five months after the PHE ends. These extensions include the following:

  • Patients’ Location – Medicare beneficiaries can continue to receive coverage for telehealth services from wherever they are located within the U.S., including their homes. Before the PHE, telehealth coverage was restricted to beneficiaries being located in hospitals and certain provider locations in order to receive coverage for telehealth.
  • Eligible Practitioners – Medicare beneficiaries can continue to receive coverage for telehealth services from physical therapists and occupational therapists.
  • Mental Health Coverage – Medicare beneficiaries can continue to receive coverage for telehealth services from mental health providers without the requirement of an in-person visit within six months of the first telehealth service with that provider nor the requirement of an in-person visit every 12 months.
  • Audio-only Telehealth – Medicare beneficiaries can continue to receive coverage for telehealth services using audio-only technology.

This is great news for Medicare beneficiaries! However, although Medicare coverage policies tend to be a bellwether for changes in private payer and Medicaid coverage, please keep in mind that private payer and Medicaid coverage for telehealth services varies by state.

Forty-three states and the District of Columbia (DC) have laws that govern private payer reimbursement of telehealth but what specific services and providers are covered varies greatly. And, while all 50 states and DC now reimburse for some types of telehealth services in Medicaid, many of the reimbursement policies have restrictions and limitations. It is important to check with your state Medicaid program or private insurer to find out what telehealth services are covered.

You can learn more about the efforts that the US Pain Foundation takes around advocacy – including ways to get involved – here.

New Kawasaki Disease Guideline Released by American College of Rheumatology and Vasculitis Foundation

The following is a press release dated March 8:

The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released a new guideline for the management of Kawasaki disease that addresses diagnostic issues relating to Kawasaki disease, the treatment of high-risk patients, and the management of convalescent patients.

Kawasaki disease is a vasculitis that is most common in children under 5 years old. It makes blood vessels in the body (particularly those that supply blood to the heart) become inflamed. This guideline is the final companion to three other ACR/VF vasculitis guidelines released in July 2021.

“Kawasaki disease continues to be an area of evolving understanding in clinical treatment,” said Mark Gorelik, MD, an Assistant Professor at Columbia University Vagelos College of Physicians and Surgeons in New York, and the lead investigator of the guideline. “There are various degrees of severity in this disease and a set of complications and therapies that rheumatologists should be aware of. These guidelines will help clinicians better treat patients by augmenting existing guidelines from the American Heart Association, especially for complex patients seen by rheumatologists.”

The guideline provides eleven treatment recommendations, a good practice statement that all Kawasaki disease patients should be initially treated with intravenous immunoglobulin (IVIG), and an ungraded position statement on the use of either non-glucocorticoid immunosuppressive therapy or glucocorticoids for patients with acute Kawasaki Disease and persistent fevers after repeated treatment with IVIG. The strong recommendations include prompt treatment of incomplete Kawasaki disease, aspirin therapy, and obtaining an echocardiogram in the setting of shock. The conditional recommendations include use of IVIG with other adjuvant agents for patients with high-risk features for IVIG resistance and/or coronary artery aneurysms.

“IVIG is the central therapy for patients with Kawasaki disease and should be administered as soon as the diagnosis of Kawasaki disease is made. IVIG significantly reduces the rate of coronary artery aneurysms,” said Dr. Gorelik.

Two recommendations in the new guideline differ from current standards. Currently, all patients with Kawasaki disease are treated essentially identically. The guideline recommends higher risk patients be treated with short courses of corticosteroids at time of first diagnosis. The guidelines also recommend that physicians can choose to use either low or high dose aspirin for therapy, since there is no evidence that either higher or lower doses are more effective for preventing vascular complications.

“Kawasaki disease is the leading cause of acquired heart disease in children,” said Joyce Kullman, Executive Director of the Vasculitis Foundation. “This guideline will hopefully take the guesswork out of determining which treatments might work best for newly diagnosed patients, or patients who have been under treatment for a while without success.”

While the guideline was being developed, the COVID-19 pandemic began. A novel multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 emerged with some features suggestive of Kawasaki disease. The ACR has published a separate clinical guidance on MIS-C, but further study is needed to understand the relationship between MIS-C and Kawasaki disease.

“Based on clinical experience with many MIS-C patients, recognition and differentiation of MIS-C from classic Kawasaki disease is important. Patients who meet criteria for Kawasaki disease should be treated using the therapies discussed in this guideline. Additional study is needed to determine optimal treatment for MIS-C with and without Kawasaki disease features,” said Dr. Gorelik.

Like many other ACR guidelines, the guideline for Kawasaki disease was developed using Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, which creates rigorous standards for judging the quality of the literature available and assigns strengths to the recommendations. The papers containing the full list of recommendations and supporting evidence is available on the ACR website.

Fifth Update of ACR COVID-19 Vaccine Guidance Supports Fourth Doses for High-Risk Rheumatic Disease Patients

The following is a press release issued by ACR today:

The American College of Rheumatology has issued an updated version of its COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and Musculoskeletal Diseases that includes support for supplemental and booster doses (often patients’ third or fourth doses), recommendations for timing of those injections in relation to immunomodulatory medication use, and revised guidance for pre- and post-exposure prophylaxis with monoclonal antibody treatment.

The guidance recommends that all rheumatic disease patients receive a booster dose after their primary vaccine series, as recommended by the CDC. Patients who are expected to have mounted an inadequate vaccine response due to using immunosuppressant treatments (as outlined in Table 3 of the guidance), should take a third mRNA vaccine dose as part of their primary vaccination series prior to their booster, for a total of four doses. These recommendations for primary vaccination, supplemental dosing, and booster doses apply regardless of whether patients have experienced natural COVID-19 infection.

The CDC currently recommends third mRNA doses be taken at least 28 days after the first two mRNA doses and booster doses be taken at least five months after completion of the primary vaccination series. Based on the availability of evidence, patients should try to take the same mRNA vaccine for their third dose but may use either if the initial brand is unknown or unavailable. No additional primary shot for the Johnson & Johnson (J&J) vaccine is approved at this time, but a booster dose of an mRNA vaccine is recommended at least two months following the primary J&J shot.

“It remains important for rheumatology providers to assess the vaccination status of all patients with rheumatic diseases,” said Dr. Jeffrey Curtis, Chair of the ACR COVID-19 Vaccine Guidance Task Force. “Initially, it might have been acceptable to just ask a patient if they have been vaccinated. There is now more nuance with supplemental and booster dose recommendations that should prompt us to ask patients not only whether they have been vaccinated, but with what, how many times, and how recently.”

The guidance also continues to support the use of pre-exposure and post-exposure monoclonal antibody prophylaxis for high-risk autoimmune and inflammatory rheumatic disease patients when/if available for use, noting that the FDA has limited the use of some monoclonal antibody therapies in light of the current conditions. For example, neither bamlanivimab and etesevimab (administered together) nor casirivimab and imdevimab, are licensed nor available under emergency use authorization (EUA) given their lack of activity against the Omicron variant, the dominant strain circulating in the U.S.

The updated recommendations can be found on the ACR website. Statements in bold are those that have been revised or added in the most current version of the document. These changes are also summarized in the Appendix Table. An important set of guiding principles, foundational assumptions and limitations are mentioned in the Supplemental Table.

A peer-reviewed manuscript with additional details on the clinical studies, data, and discussion points that influenced the recommendations has been submitted for publication to Arthritis & Rheumatology. It will be made available on the ACR website once published.

COVID-19 Infection in a Toddler

Content note: death and autopsy of a toddler

covid-19 infection in a toddler

I recently found a journal article about COVID-19 infection that everyone needs to read. Published in August, it should have been on everyone’s minds as people decided the fate of children returning to school.

Ismael Gomes, Karina Karmirian, Júlia T. Oliveira, Carolina da S.G. Pedrosa, Mayara Abud Mendes, Fernando Colonna Rosman, Leila Chimelli, Stevens Rehen. SARS-CoV-2 infection of the central nervous system in a 14-month-old child: A case report of a complete autopsy. The Lancet Regional Health – Americas, Volume 2, 2021, 100046, ISSN 2667-193X, https://doi.org/10.1016/j.lana.2021.100046.

A 14-month old Black baby girl died due to COVID-19. Four months before her death, she fell ill. Doctors assumed she had viral meningitis. She was hospitalized multiple times between then and her death. By the time they suspected pneumonia, she was just on the cusp of becoming unstable. The child died within days.

 

Findings

For those of us who need the findings in plain language:

  • Microthrombosis – Thrombosis is when a blood clot forms in a blood vessel. Microthrombosis simply means that these blood clots are incredibly small. These were found in the child’s left ventricle (heart), thyroid, and kidneys.
  • Pulmonary Congestion – Excess fluid in the lungs, which often leads to a lack of oxygen in the blood.
  • Interstitial Oedema – Swelling within the lungs in the areas surrounding the air sacs in the lungs.
  • Lymphocytic Infiltrates – A non-cancerous or benign build-up of white blood cells. These were found in the child’s right ventricle (heart), the mucous bits within the throat, tongue, stomach, intestines, liver, and more.
  • Bronchiolar Injury – A complication connected to blunt trauma and injuries during intubation. Without proper treatment, this can lead to pneumonia and other life-threatening conditions.
  • Collapsed Aalveolar Spaces – A complete or partial collapsed lung. Some of these spaces were filled with collections of protein and inflammatory cells.
  • Cortical Atrophy – The loss of brain cells called neurons. Other conditions that can lead to this include stroke, dementia, seizures, a traumatic brain injury, Huntington’s disease, AIDS. “The brain weight (635 grams) was about 33% less than normal for age.”
  • Severe Neuronal Loss – The death of brain cells. This often occurs in those with conditions that are linked to brain and cardiovascular health.
  • Hemorrhagic Foci – A type of bleeding within the brain.
  • Spongiosis – Parts of the brain turn into sponge-like tissues. Her brain became sponge-like.
  • Gliosis – A process where your body creates new or very large glial cells (which support nerve cells). These cells can cause scars and lesions on the brain.
  • Macrophages – We know that one, right?
  • Diffuse white matter edema – Swelling in the white matter.
  • Neuronal Mineralization – Tissue within the brain turns into minerals.
  • Encephalopathy – Brain swelling.
  • Overproduction of cytokines, leading to systemic inflammation.
  • Other Issues Found
    • Laryngitis.
    • Infection in the salivary glands.
    • Fewer lymph-related cells in the tonsils, thymus, appendix, and lymph nodes.
    • Swelling and blood clots within the esophagus.
    • Stomach congestion, blood in the mucous, gastritis.
    • Steatosis, or fatty liver disease.
    • Necrosis or dying tissue in and around the pancreas.
    • Blood clots within the pelvic region.
    • The taste and smell center of the brain was not around due to softening.
    • A breakdown in the blood-Cerebral Spinal Fluid barrier.

I want to highlight that MIS-C – or Multisystem Inflammatory Syndrome in Children – is similar to both Kawasaki Syndrome and Macrophage Activation Syndrome. Many of these are symptoms that those of us familiar with those conditions are very aware of. And, again, this child’s brain began to turn into a literal sponge.

 

Please continue to wear your mask, especially if you’re at higher risk.

2021 Care Rationing Survey

2021 Care Rationing Survey - #NoBodyIsDispoable Fat Legal Advocacy, Rights, & Education Project - Have you struggled with or delayed getting medical care during the pandemic? Are you a provider concerned about care rationing at your organization? Please take this survey.

The #NoBodyIsDisposable Coalition and the Fat Legal Advocacy, Rights, & Education Project have created a short survey to hear from people who are being denied medical care because of limited medical resources. Responses will be used to help advocate for fair medical treatment.

This survey was created to help gather the stories of folks who are having trouble getting medical care during COVID. Stories will be shared to create awareness and support advocacy. (Respondents can choose whether or not to share anonymously.)

Who should take the survey?

Please take the survey if you or someone you know had a hard time getting medical treatment during COVID due to limited medical personnel and supplies/equipment shortages and you suspect part or all of the reason you did not receive necessary care was based on discrimination including but not limited to your weight, disability, race, age, or other factors.

Take the survey if you have been delaying necessary medical care because you worry if you do get COVID that you will be deprioritized for life-saving medical treatment based on your weight, disability, race, age, or other factors.

Take the survey if you work at a health care organization and have concerns about the care rationing policy, or how it is implemented.

Link to the Survey

The survey is available in English and Spanish.

Please help spread the word. They will be reviewing answers on an ongoing basis.